North America Bloodstream Infection Testing Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Sample Type, By Technology, By End-user, By Region, And Segment Forecasts, 2023 - 2030

The North America bloodstream infection testing market size is expected to reach USD 408.53 million by 2030. The market is expected to expand at a CAGR of 3.6% from 2023 to 2030. Increasing demand for advanced bloodstream infection testing methods, the introduction of culture-independent tests, and a rising number of CROs and forensic & research laboratories are among the major factors expected to drive growth in the bloodstream infection testing market.

Bloodstream infections (BSIs) are associated with adverse health-economic and clinical outcomes. A substantial portion (30-40%) of severe sepsis and septic shock cases can be attributed to culture-proven BSIs, which exhibit a sharp decline in survival rates if appropriate antimicrobial therapy is not administered within the first 24 hours. To mitigate this risk, clinicians often resort to broad-spectrum antimicrobial therapy without precise pathogen identification, leading to the selection and spread of resistant pathogens.

Implementing rapid BSI detection methods with antibiotic susceptibility testing can revolutionize infection control practices, therapeutic management, and clinical decision-making. This approach has the potential to reduce unnecessary antimicrobial prescriptions, lower the prevalence of adverse outcomes, and optimize resource utilization in healthcare settings.

The key players in the regional bloodstream infection testing market, such as F. Hoffmann-La Roche Ltd., bioMérieux SA, T2 Biosystems, BD, Cepheid, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in June 2023, T2 Biosystems, Inc., a major provider of rapid sepsis detection solutions in the U.S., established a collaborative partnership with Vanderbilt University Medical Center's Learning Healthcare System (LHS) Platform.

As part of the collaboration, Vanderbilt University Medical Center will integrate and assess the FDA-cleared T2Bacteria Panel in a clinical setting. A prospective study will be conducted to evaluate the impact of utilizing the T2Bacteria Panel directly from blood samples, focusing on improving antibiotic usage and clinical interventions for patients diagnosed with bloodstream infections. This partnership indicates a significant step forward in advancing sepsis management and underscores both organizations’ commitment to driving positive change in healthcare delivery.

North America Bloodstream Infection Testing Market Report Highlights

• Based on the product, the reagents and consumables segment accounted for the largest revenue share owing to the easy availability and frequent purchase of screening products for donors and recipients
• Based on sample type, the blood culture segment dominated the market owing to the launch of automated blood culture systems and their improved efficacy
• Based on technology, the PCR segment held the largest revenue share in 2022 and is the most preferred technology among doctors and patients
• Hospital and diagnostic centers led the end-user segment in 2022, which is attributable to the increasing number of hospitalizations
• The U.S. dominated the North American bloodstream infection testing market in 2022 due to favorable reimbursement policies, the high prevalence of infections, and the presence of a large patient pool in the country

This product will be delivered within 1-3 business days.